Napabucasin

Drug Profile

Napabucasin

Alternative Names: BB 608; BBI 608 DP1; BBI 608 DP2A; BBI-608; DP1; DP2A

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Boston Biomedical
  • Developer Boston Biomedical; Sumitomo Dainippon Pharma
  • Class Antineoplastics; Furans; Naphthoquinones; Small molecules
  • Mechanism of Action Beta catenin inhibitors; Cell death stimulants; STAT3 transcription factor inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Gastric cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer; Gastric cancer; Non-small cell lung cancer
  • Phase I/II Glioblastoma; Hepatocellular carcinoma; Mesothelioma; Solid tumours
  • Phase I Gastrointestinal cancer; Haematological malignancies; Pancreatic cancer

Most Recent Events

  • 13 Dec 2016 Boston Biomedical plans a phase III trial in Pancreatic cancer (Metastatic disease, Combination therapy) in USA (NCT02993731)
  • 14 Nov 2016 Napabucasin receives Orphan Drug status for Pancreatic cancer in USA
  • 01 Nov 2016 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02826161)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top